ENXTPA:ABVXBiotechs
Assessing Abivax (ENXTPA:ABVX) Valuation Following Phase 3 Patient-Reported Outcomes for Obefazimod in Ulcerative Colitis
ABIVAX Société Anonyme (ENXTPA:ABVX) just shared patient-reported outcomes from its Phase 3 trial for obefazimod in adults with ulcerative colitis. These findings shed light on how patients actually experience the drug’s effects beyond clinical endpoints.
See our latest analysis for ABIVAX Société Anonyme.
After releasing the latest trial results and earning a spot in the Euronext 150 Index, ABIVAX Société Anonyme's stock has been on an impressive run. Momentum remains strong, with a 90-day...